Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “outperform” rating restated by equities researchers at BMO Capital Markets in a report issued on Friday. They presently have a $195.00 target price on the specialty pharmaceutical company’s stock. BMO Capital Markets’ target price indicates a potential upside of 55.56% from the company’s previous close.
A number of other analysts have also issued reports on JAZZ. Leerink Swann reissued an “outperform” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Friday, June 17th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Saturday, June 18th. Mizuho reaffirmed a “buy” rating and set a $193.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 21st. Zacks Investment Research lowered Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, July 20th. Finally, Piper Jaffray Cos. cut their price objective on Jazz Pharmaceuticals PLC from $188.00 to $178.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $185.00.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 125.35 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $108.50 and a 52 week high of $160.00. The company has a 50-day moving average price of $124.95 and a 200-day moving average price of $139.82. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 22.04 and a beta of 0.96.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $2.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.80 by $0.17. The firm earned $381 million during the quarter, compared to analysts’ expectations of $376.40 million. Jazz Pharmaceuticals PLC had a net margin of 25.46% and a return on equity of 28.39%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.41 EPS. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post $9.97 EPS for the current year.
In other Jazz Pharmaceuticals PLC news, CMO Karen L. Smith bought 580 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Wednesday, July 13th. The stock was acquired at an average cost of $143.63 per share, with a total value of $83,305.40. Following the completion of the acquisition, the chief marketing officer now owns 13,574 shares of the company’s stock, valued at $1,949,633.62. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $126.17, for a total transaction of $25,234.00. Following the completion of the sale, the senior vice president now directly owns 17,325 shares of the company’s stock, valued at $2,185,895.25. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. Fiera Capital Corp acquired a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $46,955,000. Renaissance Technologies LLC boosted its stake in shares of Jazz Pharmaceuticals PLC by 1,044.1% in the first quarter. Renaissance Technologies LLC now owns 215,100 shares of the specialty pharmaceutical company’s stock worth $28,081,000 after buying an additional 196,300 shares during the last quarter. Polar Capital LLP acquired a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $25,560,000. JPMorgan Chase & Co. boosted its stake in shares of Jazz Pharmaceuticals PLC by 20.0% in the first quarter. JPMorgan Chase & Co. now owns 1,074,731 shares of the specialty pharmaceutical company’s stock worth $140,307,000 after buying an additional 179,454 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Jazz Pharmaceuticals PLC by 193.8% in the second quarter. Point72 Asset Management L.P. now owns 218,900 shares of the specialty pharmaceutical company’s stock worth $30,933,000 after buying an additional 144,400 shares during the last quarter. 88.25% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.